Back to Journals » Vascular Health and Risk Management » Volume 5

Comparison of prasugrel and clopidogrel in patients with acute coronary syndrome undergoing percutaneous coronary intervention

Authors Norgard N, Abu-Fadel M

Published 21 October 2009 Volume 2009:5 Pages 873—882


Review by Single-blind

Peer reviewer comments 2

Nicholas B Norgard,1 Mazen Abu-Fadel2

1University at Buffalo, School of Pharmacy and Pharmaceutical Sciences, Buffalo, NY, USA; 2University of Oklahoma Health Sciences Center, Cardiovascular Section, Oklahoma City, OK, USA

Abstract: Antiplatelet agents are the cornerstone of treatment for patients with acute coronary syndrome (ACS) undergoing percutaneous coronary intervention (PCI). Clopidogrel, when added to aspirin, has demonstrated considerable success at reducing thrombotic complications of ACS and/or PCI compared to aspirin alone and is standard of care for the management of patients with ACS and in patients undergoing PCI. Prasugrel is a novel thienopyridine antiplatelet agent recently approved for the treatment of patients with ACS undergoing PCI. Prasugrel provides greater and more consistent platelet inhibition than clopidogrel due to earlier and more extensive formation of its active metabolite. The enhanced platelet inhibition with prasugrel led to a reduction in major adverse cardiovascular events in patients with moderate to high risk ACS scheduled for PCI in the phase 3 TRITON-TIMI 38 trial. This benefit was seen more in patients suffering a STEMI and those with diabetes. However, this reduction in events was met with a significant increase in the risk of bleeding which overcame prasugrel’s benefit in certain groups. Future studies with prasugrel are needed to determine its optimal utilization to minimize bleeding risks and evaluate its outcomes in ACS and safety profile in special patient populations.

Keywords: clopidogrel, prasugrel, percutaneous coronary intervention, acute coronary syndrome

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF] 


Other article by this author:

Profound thrombocytopenia after primary exposure to eptifibatide

Nicholas B Norgard, Brian T Badgley

Drug, Healthcare and Patient Safety 2010, 2:163-167

Published Date: 21 September 2010

Readers of this article also read:

Metabolic biomarkers for predicting cardiovascular disease

Montgomery JE, Brown JR

Vascular Health and Risk Management 2013, 9:37-45

Published Date: 29 January 2013

The potential benefit of stem cell therapy after stroke: an update

Banerjee S, Williamson DA, Habib N, Chataway J

Vascular Health and Risk Management 2012, 8:569-580

Published Date: 10 October 2012

Management of high-risk popliteal vascular blunt trauma: clinical experience with 62 cases

Ali Pourzand, Bassir A Fakhri, Ramin Azhough, et al

Vascular Health and Risk Management 2010, 6:613-618

Published Date: 14 July 2010

Heart rate control with adrenergic blockade: Clinical outcomes in cardiovascular medicine

David Feldman, Terry S Elton, Doron M Menachemi, et al

Vascular Health and Risk Management 2010, 6:387-397

Published Date: 24 May 2010

Low use of statins and other coronary secondary prevention therapies in primary and secondary care in India

Krishna K Sharma, Rajeev Gupta, Aachu Agrawal, et al

Vascular Health and Risk Management 2009, 5:1007-1014

Published Date: 20 November 2009

Randomized study to compare valsartan ± HCTZ versus amlodipine ± HCTZ strategies to maximize blood pressure control

Dion Zappe, Cheraz Cherif Papst, Philippe Ferber, et al.

Vascular Health and Risk Management 2009, 5:883-892

Published Date: 22 October 2009

Orlistat in the prevention of diabetes in the obese patient

Marcio C Mancini, Alfredo Halpern

Vascular Health and Risk Management 2008, 4:325-336

Published Date: 11 April 2008